Cathy Eng, MD
Medical Oncology · Nashville, TNNPI 1558469767
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $152,376 of the $231,080 with a category attached, or 65.9%. 39 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 28.3% of the total. Among medical oncology clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 188 payments — averaging $1229.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$65K
- Bayer$35K
- GSK$20K
- Array Biopharma Inc$16K
- Taiho Oncology, Inc.$12K
- Boehringer Ingelheim International GmbH$12K
- plus $71K from 33 others
Across 243 payments — averaging $14,767 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$2.1M
- Sumitomo Pharma America, Inc.$660K
- Merck$395K
- Eli Lilly$133K
- Genentech, Inc.$132K
- Karyopharm Therapeutics Inc.$74K
- plus $135K from 7 others
What the payments were for
- Consulting fees$152,37666%
- Speaking & faculty fees$48,80521%
- Travel & lodging$22,28110%
- Food & beverage$7,6183%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FRUZAQLA$42,210
- Stivarga$17,177
- BRAFTOVI$15,346
- Lonsurf$8,017
- JEMPERLI$4,400
- TAS-102$3,447
- ZYNYZ$3,435
- MEKTOVI$3,403
- Avastin$3,293
- Non-Covered$2,800
- TECENTRIQ$2,719
- Tarceva$2,640
- Vitrakvi$2,625
- LUMAKRAS$2,596
- GENERAL PAIN MANAGEMENT$2,400
- LENVIMA$2,280
- FOUNDATIONONE CDX$1,979
- Non-Covered Product$990
- FOUNDATIONONE LIQUID CDX$433
- ZUSDURI$400
How this compares
$231,080 in reported general payments places this provider in the 90th percentile of 101 medical oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Nashville
- William PaoNashville$838K
- Dana ThompsonNashville$339K
- Robert RamirezNashville$321K
- Mace RothenbergNashville$318K
- Melissa JohnsonNashville$290K
- David SpigelNashville$167K
- Michael GibsonNashville$141K
- Jordan BerlinNashville$120K
- Vandana AbramsonNashville$98K
- Leora HornNashville$98K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.